Restart Life Sciences Corp.
HEAL
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.43% | -45.29% | -67.96% | -70.92% | -49.28% |
| Depreciation & Amortization | -20.00% | -20.00% | -20.00% | -20.00% | -28.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.69% | -45.22% | -72.02% | -72.62% | -49.50% |
| Operating Income | -25.32% | 36.86% | 72.02% | 72.62% | 42.10% |
| Income Before Tax | 100.06% | 345.55% | 70.63% | 72.57% | 80.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.06% | 345.55% | 70.63% | 72.57% | 80.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.06% | 345.55% | 70.63% | 72.57% | 80.45% |
| EBIT | -25.32% | 36.86% | 72.02% | 72.62% | 42.10% |
| EBITDA | -25.54% | 36.99% | 72.13% | 72.68% | 42.17% |
| EPS Basic | 100.00% | 344.09% | 70.59% | 73.13% | 80.94% |
| Normalized Basic EPS | -23.08% | 37.93% | 70.83% | 73.21% | 35.00% |
| EPS Diluted | 61.90% | 198.66% | 70.59% | 73.13% | 73.32% |
| Normalized Diluted EPS | -10.77% | 41.38% | 70.83% | 73.21% | 35.00% |
| Average Basic Shares Outstanding | 13.29% | 0.78% | 0.66% | 1.69% | 2.94% |
| Average Diluted Shares Outstanding | 25.70% | 4.12% | 0.66% | 1.69% | 2.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |